Cas12a(cpf1) crRNA
Accelerate precision gene editing with GenScript's custom synthetic crRNA for Cas12a(cpf1) projects.
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Custom synthetic CRISPR RNA (crRNA) for Cas12a-based gene editing, screening, and diagnostic applications. Our bespoke service offers extensive customization options and expert support to guide you through every step.
Easily design high-performance crRNA with our intelligent GenCRISPR gRNA Design Tool, which ranks guides based on on-target and off-target scores for optimal results.
De-risk your CRISPR pipeline with scalable cGMP guide RNA
Tuesday, April 8, 2025 – 16:00 BST / 17:00 CEST / 11:00 EDT / 08:00 PDT
Join us for an exclusive webinar with Dr. Pedro Teh as he explores how expert guide RNA (gRNA) manufacturing services can help accelerate your CRISPR-based therapeutic development in line with current good manufacturing practices (cGMP).
As a trusted partner in cell and gene therapy, GenScript provides high-quality, scalable, and regulatory-compliant gRNA for CRISPR systems including Cas9, Cas12a, prime editing, and base editing.
Discover how GenScript's cGMP synthesis capabilities and state-of-the-art production facility ensures a streamlined 30-day turnaround for clinical-grade gRNA, and see how comprehensive documentation support – including Drug Master Files (DMFs) – can facilitate smooth investigational new drug (IND) submissions and regulatory approvals.
Whether you're in early-stage research or preparing for clinical trials, this webinar will show you how GenScript's expertise in cGMP nucleic acid manufacturing, quality control, and regulatory support can help de-risk and accelerate your CRISPR therapeutic pipeline.
Key learning objectives:
- Learn about cGMP guide RNA manufacturing and quality control processes
- Explore a range of gene editing approaches that can be supported by cGMP gRNA services
- Understand how expert documentation support simplifies IND submissions and regulatory approvals
- Learn why procuring RUO to cGMP gRNA from a single vendor streamlines and de-risks the development process for CRISPR therapies
Who should attend?
Scientists and decision-makers from biopharma, biotech, and academic institutions using gene editing for discovery or preclinical research.
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
